Dimethyl fumarate is an inhibitor of pathological angiogenesis
Cellular Signalling · 2025
DOI: 10.1016/j.cellsig.2025.112106 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2025. Verfasst von Pei Qin Ng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plant Sciences, University of Cambridge, Downing Street, Cambridge CB2 3EA, Cambridgeshire, UK. Hauptthemen laut MEDLINE: Dimethyl Fumarate, Neovascularization, Pathologic, Angiogenesis Inhibitors. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BrightFocus Foundation, University of New South Wales.
Abstract (Originalsprache)
Vascular endothelial growth factor (VEGF), a pro-angiogenic molecule, supports blood vessel growth during wound healing but also drives pathological neovascularization in blinding eye diseases such as neovascular age-related macular degeneration (nAMD). Dimethyl fumarate (DMFu), an FDA-approved drug for multiple sclerosis, has shown promising anti-inflammatory properties in the retinal pigment epithelium, a crucial structure disrupted in nAMD. Here, we extend the therapeutic potential of DMFu by discerning the anti-angiogenic capabilities of DMFu in choroidal and retinal endothelial cells. Choroidal endothelial cell proliferation was significantly attenuated by DMFu in the mouse choroidal sprouting assay. Even in the presence of VEGF, DMFu disrupted cell migration and tube formation in human microvascular retinal endothelial cells (HRECs). Bulk RNA sequencing highlighted that DMFu successfully ameliorated the expression of VEGF-controlled gene expression. Weighted gene co-expression network and gene set enrichment analyses confirmed downregulation of pathways involved in branching blood vessel morphogenesis but also revealed novel transcriptional mechanisms of action, including control of microtubule transport and ATP synthesis coupled electron transport. DMFu induced a decrease in maximal mitochondrial respiration, an increase in glycolysis and glycolytic capacity and reduced Complex II protein expression of the SDHB subunit on western blot. Such metabolic rewiring may limit the bioenergetic demands required to support angiogenic growth. With therapies available for nAMD being both limited and invasive, DMFu is a contender to be rapidly repurposed as an oral, patient-friendly therapeutic alternative.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Plant Sciences, University of Cambridge, Downing Street, Cambridge CB2 3EA, Cambridgeshire, UK.
- School of Optometry and Vision Science, University of New South Wales, Kensington, NSW 2052, Australia.
- Schepens Eye Research Institute of Mass Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA.
- School of Optometry and Vision Science, University of New South Wales, Kensington, NSW 2052, Australia. Electronic address: daisy.shu@unsw.edu.au.
Förderung
- BrightFocus Foundation
- University of New South Wales
Zitieren
APA
Ng, P. Q., Huang, K., McLellan, F. C., Yang, M., Lennikov, A., Hu, Z., Chaudhary, S., Appiah, A. C., Vuong, M. L., & Shu, D. Y. (2025). Dimethyl fumarate is an inhibitor of pathological angiogenesis. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2025.112106
Vancouver
Ng PQ, Huang K, McLellan FC, Yang M, Lennikov A, Hu Z, et al. Dimethyl fumarate is an inhibitor of pathological angiogenesis. Cellular Signalling. 2025. doi:10.1016/j.cellsig.2025.112106
BibTeX
@article{Ng2025,
author = {Ng, Pei Qin and Huang, Kelvin and McLellan, Fergus C and Yang, Menglu and Lennikov, Anton and Hu, Zhengping and Chaudhary, Suman and Appiah, Alena C and Vuong, Mong Linh and Shu, Daisy Y},
title = {Dimethyl fumarate is an inhibitor of pathological angiogenesis},
journal = {Cellular Signalling},
year = {2025},
doi = {10.1016/j.cellsig.2025.112106}
}
EUVIMED